Compare Nutrien Ltd (NTR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Natera Inc. Common Stock — how do they compare? Nutrien Ltd trades at $69.87 (market cap $33.13B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Nutrien Ltd pays a 3.16% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 60 Days and Natera Inc. Common Stock for 0 Days on average.
| NTR | NTRA | |
|---|---|---|
Market Cap | $33.13B | $57.03B |
Volume | 2,165,412 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $425.64 |
52-Week Low | $53.64 | $179.42 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $44.94B | $56.18B |
Dividend Yield | 3.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTR trades at $69.87, up 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. The company demonstrates solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation ratios including P/E of 14.11. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations. Analyst sentiment remains positive with 60.61% buy ratings and $77.29 consensus target.
NTR presents a compelling value opportunity with reasonable valuations and strong cash flow generation, though facing headwinds from fertilizer industry challenges and competitive pressures. The stock's current discount to analyst targets suggests potential upside, but investors should monitor execution on cost discipline and volume recovery amid fluctuating commodity prices and geopolitical factors affecting fertilizer markets.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
